Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Nebraska for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Nebraska only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Nebraska (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Luke Nordquist (NPI 1538149414)

Field	Value
Entity Type	Individual
Organization	Luke Nordquist
Address	17607 Gold Plz
City	Omaha
State	NE
ZIP	68130
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	January 18, 2006

Payer Source	Total Paid
Medicare	$3.7M
Medicaid	$0

Key Findings

This provider is effectively single‑payer: reported Total Medicare revenue of $3.7M and has no Medicaid billing on file, so all claims activity on record is Medicare‑driven. That payer concentration means analyses of utilization and financial performance will reflect Medicare policy and pricing rather than any Medicaid mix dynamics.

Revenue is highly concentrated in a few high‑impact oncology codes: the precomputed top 3 Medicare codes account for 71.8% of this provider's total Medicare revenue. Those top three are A9607 ($1.9M, 50.8%), A9596 ($467.8K, 12.7%), and J9035 ($304.1K, 8.3%), indicating most earnings come from a narrow set of therapeutic and imaging services.

Clinical/service profile points to a radiopharmaceutical and infusion‑heavy oncology practice: A9607 (Lutetium lu 177) and A9596 (Gallium ga‑68) together produce the majority of revenue from radioligand therapy and PET diagnostics, and imaging codes such as 78815 (PET/CT, $133.7K) and 78306 (bone scan, $22K) are also present. This mix suggests the practice both performs diagnostic nuclear medicine and delivers therapeutic radiopharmaceutical care rather than only office‑based oncology.

The practice also shows very high throughput for several infused oncology drugs and related procedures: J9035 (bevacizumab) generated $304.1K and ranks #3 of 1852 providers nationally (100th percentile, described as an "extreme outlier, far above typical national volume"), J0897 (denosumab) produced $280.8K and is "notably above typical national volume," and J9217 (leuprolide) generated $238.3K and ranks #1 of 3683 providers (100th percentile). Those rankings indicate this provider is a major national user of specific oncology injectables and depot therapies, supporting substantial infusion operations.

Several service‑level indicators corroborate a high procedural throughput model: 36415 (blood draw) shows 2.3K claims and ranks in the 99th percentile, while chemotherapy/administration codes such as 96402 rank #1 of 4765 providers (100th percentile) and 96413 appear in the top list. These patterns point to frequent office or outpatient infusion encounters and associated staffing and infusion‑suite resource needs.

Competitive standing is mixed by code: for some radiopharmaceutical diagnostics and therapies the provider is above typical national volume (A9596 ranks #7 of 168, 96th percentile), but for A9607 (Lu‑177) the provider ranks #15 of 44 (67th percentile) — a typical, unremarkable national position for that code. In contrast, the provider is a clear outlier and major national participant for certain injectable treatments (J9035 and J9217 rank at or near the top nationally), so competitive influence varies by service line.

Operational risk and strategic implications flow from the concentrated revenue base: with 71.8% of Medicare revenue tied to three codes, the practice is exposed to utilization shifts, reimbursement changes, or access limits affecting those specific radiopharmaceuticals and high‑cost injectables. Payers or partners evaluating contracting or network strategy should weight that concentration when forecasting revenue sensitivity to code‑level policy changes.

The provider has long tenure in the Medicare program, with NPI enumerated 2006‑01‑18 (~20 years ago), which aligns with the scale of specialized services reported and suggests an established practice with time to build referral relationships and specialized service lines. Longevity combined with code‑level outlier positions for several infusion and radiopharmaceutical services supports the profile of a stable, specialty oncology operator rather than a newly entering practice.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

41 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
A9607	Lutetium lu 177 vipivotide tetraxetan, therapeutic, 1 millicurie	9,600	$190	$1.9M
A9596	Gallium ga-68 gozetotide, diagnostic, (illuccix), 1 millicurie	570	$830	$467.8K
J9035	Injection, bevacizumab, 10 mg	6,610	$50	$304.1K
J0897	Injection, denosumab, 1 mg	15,600	$20	$280.8K
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	1,830	$130	$238.3K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	120	$1,080	$133.7K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,000	$90	$87.7K
84403	The lab analyst performs a test to measure total testosterone, typically in patient serum.	1,730	$30	$43.3K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	740	$50	$39.7K
84153	The lab analyst performs testing for total prostate specific antigen, PSA, typically on serum or plasma samples using laboratory analyzers. PSA is a protein the prostate gland produces, and…	1,920	$20	$34.6K

Showing 1–10 of 41

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 41 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Nebraska Distribution

Luke Nordquist — 15 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Nebraska

Full comparison — all codes billed, vs. state median

41 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
A9607	1	10	9,070	$190	$1.8M
A9596	1	10	280	$820	$243.3K
J0897	4	200	2,040	$20	$62.7K
J9035	1	10	30	$50	$47.1K
78815	13	60	70	$380	$32.7K
J9217	1	50	110	$130	$20.6K
96413	32	80	60	$90	$18.2K
74177	56	160	170	$80	$15.3K
99214	74	3,210	110	$70	$14.9K
79101	3	10	80	$100	$8.7K

Showing 1–10 of 41

Related Providers

Other providers that share a Tax Identification Number (TIN) with Luke Nordquist, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Samuel Mehr	NE	Nuclear Medicine Physician	$2.5M	$0
Hadi Zahra	NE	Radiation Oncology Physician	$200.2K	$0
Amir Zahra	NE	Radiation Oncology Physician	$165.2K	$0
Jason Grennan	NE	Diagnostic Radiology Physician	$157K	$3.3K
Mohammed Quraishi	NE	Diagnostic Radiology Physician	$104K	$3.2K
Jonathan Jaksha	NE	Diagnostic Radiology Physician	$104.1K	$2.9K
Veronica Ruvo	NC	Diagnostic Radiology Physician	$96.8K	$0
Matthew Jaksha	NE	Diagnostic Radiology Physician	$88.3K	$0
Farid Thanawalla	TN	Vascular & Interventional Radiology Physician	$74.3K	$80

Nearby Providers

Other providers in the same ZIP code as Luke Nordquist, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Alegent Creighton Health	NE	General Acute Care Hospital	$0	$4.3M
Dean Arkfeld	NE	Ophthalmology Physician	$1.4M	$0
Omegavision PC	NE	Optometrist	$0	$1.4M
New Century Physicians Of Nebraska LLC	NE	Emergency Medicine Physician	$0	$917.9K
Heartland Family First Medical Clinic, LLC	NE	Pediatrics Physician	$0	$899.3K
Lakeside Ambulatory Surgical Center LLC	NE	Ambulatory Surgical Clinic/Center	$557.1K	$0
Omaha Anesthesia Associates LLC	NE	Anesthesiology Physician	$0	$517.9K
Children's Rehab - Occupational Therapy	NE	Pediatric Occupational Therapist	$0	$388.1K
Brandon Menke	NE	Ophthalmology Physician	$372.2K	$0
Beyond Care Pediatrics LLC	NE	Pediatrics Physician	$0	$354.5K

Luke Nordquist — Billing Profile & Reimbursement Data

Sign up for Luke Nordquist — Billing Profile & Reimbursement Data policy alerts

Luke Nordquist — Billing Profile & Reimbursement Data

Sign up for Luke Nordquist — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References